QV Investors Inc. Has $16.69 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

QV Investors Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,660 shares of the company's stock after selling 4,280 shares during the quarter. Johnson & Johnson accounts for 1.7% of QV Investors Inc.'s portfolio, making the stock its 17th largest holding. QV Investors Inc.'s holdings in Johnson & Johnson were worth $16,693,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of JNJ. NBC Securities Inc. raised its position in Johnson & Johnson by 102,995.0% during the first quarter. NBC Securities Inc. now owns 41,238 shares of the company's stock valued at $6,838,000 after buying an additional 41,198 shares during the period. Enterprise Bank & Trust Co boosted its position in Johnson & Johnson by 3.6% during the first quarter. Enterprise Bank & Trust Co now owns 5,283 shares of the company's stock valued at $876,000 after purchasing an additional 185 shares during the last quarter. Worth Asset Management LLC increased its holdings in Johnson & Johnson by 49.0% in the first quarter. Worth Asset Management LLC now owns 2,391 shares of the company's stock worth $396,000 after buying an additional 786 shares during the last quarter. Fiduciary Alliance LLC lifted its stake in Johnson & Johnson by 1.3% in the first quarter. Fiduciary Alliance LLC now owns 79,753 shares of the company's stock valued at $13,226,000 after acquiring an additional 1,015 shares during the last quarter. Finally, Baker Tilly Wealth Management LLC grew its position in Johnson & Johnson by 38.4% in the first quarter. Baker Tilly Wealth Management LLC now owns 8,004 shares of the company's stock worth $1,327,000 after acquiring an additional 2,221 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on JNJ shares. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their target price for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Finally, Barclays decreased their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Price Performance

Shares of JNJ stock traded down $0.95 during mid-day trading on Tuesday, reaching $154.45. The company's stock had a trading volume of 8,205,196 shares, compared to its average volume of 7,944,682. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company has a market cap of $371.63 billion, a P/E ratio of 23.23, a PEG ratio of 2.56 and a beta of 0.42. The firm's 50-day moving average is $154.19 and its two-hundred day moving average is $153.67.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.37%. Johnson & Johnson's payout ratio is currently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.